logo_bg We Can Cure Alzheimer's Now

Group Reports Potential Alzheimer’s Treatments in Growing Number of Phase 2 and Phase 3 Studies

The number of clinical trials evaluating possible treatments for Alzheimer’s disease is on the increase, according to a recent analysis conducted by Researchers Against Alzheimer’s (RA2), a global network of Alzheimer’s researchers that is part of a non-profit organization promoting the study and treatment of this disease, called Us Against Alzheimer’s.

The results were recently presented at this year’s Us Against Alzheimer’s National Alzheimer’s Summit, held in Washington’s, D.C., under the title “Where are We on the Path to 2025.”

To date, there are 57 Phase 2 and 23 Phase 3 ongoing clinical trials to test potential Alzheimer’s medications, and 19 such drugs are estimated to come onto the market in the next five years. The analysis not only showed that the science behind Alzheimer’s is moving forward, but also that clinical trials are keeping up with drug development and research investigating new ways to combat the disease.

“I am encouraged to see such a range of approaches to treating Alzheimer’s in Phase II development,” David Morgan, CEO of the University of South Florida’s Byrd Alzheimer’s Institute, said in a news release. “There is much work that still needs to be done, but the drugs in Phase II clinical trials offer a great deal of hope for the future.”

Alzheimer’s disease is complex, and not all treatments are effective in all patients. The more options that are under evaluation, the better. Several treatments under evaluation aim to improve certain symptoms, such as agitation, cognitive loss or depression, while others are being studied for their ability to prevent or delay the appearance of symptoms in people at risk of Alzheimer’s.

Full Story by Joana Fernandes, PhD